Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2005 Jul;60(7):576–581. doi: 10.1136/thx.2004.037622

Differential expression of VASP in normal lung tissue and lung adenocarcinomas

L Dertsiz 1, G Ozbilim 1, Y Kayisli 1, G Gokhan 1, A Demircan 1, U Kayisli 1
PMCID: PMC1747468  PMID: 15994266

Abstract

Background: Vasodilator stimulated phosphoprotein (VASP) is associated with focal adhesions and is thought to have an important role in actin filament assembly and cell motility. We hypothesise that an increase in the expression of VASP is involved in the progression and invasion of lung adenocarcinomas in parallel to tumour progression. A study was undertaken to analyse VASP expression in normal lung tissue and lung adenocarcinomas.

Methods: Human lung tissues with adenocarcinomas (n = 26) were used. Normal lung tissue specimens (n = 14) were taken from areas a standard distance (3 cm) from resected adenocarcinomas of patients who underwent surgical lung resection. Adenocarcinomas were classified according to pathological staging and histopathological grades. Tissues were stained for VASP using immunohistochemistry.

Results: Normal lung pneumocytes showed no VASP expression while alveolar macrophages had the strongest immunoreactivity for VASP. Bronchial epithelium (surface epithelium, goblet cells) and bronchial gland cells had a very weak immunoreactivity for VASP. Adenocarcinomas had significantly greater VASP expression than normal epithelium (p<0.001). Moreover, VASP expression in adenocarcinomas increased significantly with more advanced tumour stage (p<0.001).

Conclusions: The spatial and differential expression of VASP in normal lung tissue and lung adenocarcinomas suggests that it is likely to be involved in the differentiation of normal lung cells to adenocarcinomas. The significant increase in the expression of VASP in adenocarcinomas in parallel to pathological staging suggests that it may regulate the invasive behaviour of lung adenocarcinomas as adenocarcinoma invasion is increased in more advanced tumours.

Full Text

The Full Text of this article is available as a PDF (354.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asamura H., Ando M., Matsuno Y., Shimosato Y. Histopathologic prognostic factors in resected adenocarcinomas: is nuclear DNA content prognostic? Chest. 1999 Apr;115(4):1018–1024. doi: 10.1378/chest.115.4.1018. [DOI] [PubMed] [Google Scholar]
  2. Bacus S., Flowers J. L., Press M. F., Bacus J. W., McCarty K. S., Jr The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. Am J Clin Pathol. 1988 Sep;90(3):233–239. doi: 10.1093/ajcp/90.3.233. [DOI] [PubMed] [Google Scholar]
  3. Buccheri G., Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J. 1994 Jul;7(7):1350–1364. doi: 10.1183/09031936.94.07071350. [DOI] [PubMed] [Google Scholar]
  4. Chen Lihua, Daum Günter, Chitaley Kanchan, Coats Scott A., Bowen-Pope Daniel F., Eigenthaler Martin, Thumati Naresh R., Walter Ulrich, Clowes Alexander W. Vasodilator-stimulated phosphoprotein regulates proliferation and growth inhibition by nitric oxide in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004 Jun 3;24(8):1403–1408. doi: 10.1161/01.ATV.0000134705.39654.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fong K. M., Sekido Y., Gazdar A. F., Minna J. D. Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax. 2003 Oct;58(10):892–900. doi: 10.1136/thorax.58.10.892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fontanini G., De Laurentiis M., Vignati S., Chinè S., Lucchi M., Silvestri V., Mussi A., De Placido S., Tortora G., Bianco A. R. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 1998 Jan;4(1):241–249. [PubMed] [Google Scholar]
  7. Gibbs A. R., Thunnissen F. B. Histological typing of lung and pleural tumours: third edition. J Clin Pathol. 2001 Jul;54(7):498–499. doi: 10.1136/jcp.54.7.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Guzeloglu-Kayisli Ozlem, Kayisli Umit A., Al-Rejjal Rafat, Zheng Wenxin, Luleci Guven, Arici Aydin. Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. J Clin Endocrinol Metab. 2003 Oct;88(10):5017–5026. doi: 10.1210/jc.2003-030414. [DOI] [PubMed] [Google Scholar]
  9. Halbrügge M., Eigenthaler M., Polke C., Walter U. Protein phosphorylation regulated by cyclic nucleotide-dependent protein kinases in cell extracts and in intact human lymphocytes. Cell Signal. 1992 Mar;4(2):189–199. doi: 10.1016/0898-6568(92)90082-j. [DOI] [PubMed] [Google Scholar]
  10. Halbrügge M., Walter U. Purification of a vasodilator-regulated phosphoprotein from human platelets. Eur J Biochem. 1989 Oct 20;185(1):41–50. doi: 10.1111/j.1432-1033.1989.tb15079.x. [DOI] [PubMed] [Google Scholar]
  11. Holt M. R., Critchley D. R., Brindle N. P. The focal adhesion phosphoprotein, VASP. Int J Biochem Cell Biol. 1998 Mar;30(3):307–311. doi: 10.1016/s1357-2725(97)00101-5. [DOI] [PubMed] [Google Scholar]
  12. Horstrup K., Jablonka B., Hönig-Liedl P., Just M., Kochsiek K., Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem. 1994 Oct 1;225(1):21–27. doi: 10.1111/j.1432-1033.1994.00021.x. [DOI] [PubMed] [Google Scholar]
  13. Huang C. L., Taki T., Adachi M., Konishi T., Higashiyama M., Kinoshita M., Hadama T., Miyake M. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int J Oncol. 1998 Mar;12(3):553–563. doi: 10.3892/ijo.12.3.553. [DOI] [PubMed] [Google Scholar]
  14. Ichinose Y., Hara N., Ohta M., Yano T., Maeda K., Asoh H., Katsuda Y. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer ? A multivariate prognostic factor analysis of 151 patients. J Thorac Cardiovasc Surg. 1993 Jul;106(1):90–94. [PubMed] [Google Scholar]
  15. Janssen-Heijnen M. L. G., Smulders S., Lemmens V. E. P. P., Smeenk F. W. J. M., van Geffen H. J. A. A., Coebergh J. W. W. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax. 2004 Jul;59(7):602–607. doi: 10.1136/thx.2003.018044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kayisli Umit A., Demir Ramazan, Erguler Gamze, Arici Aydin. Vasodilator-stimulated phosphoprotein expression and its cytokine-mediated regulation in vasculogenesis during human placental development. Mol Hum Reprod. 2002 Nov;8(11):1023–1030. doi: 10.1093/molehr/8.11.1023. [DOI] [PubMed] [Google Scholar]
  17. Kayisli Umit A., Selam Belgin, Demir Ramazan, Arici Aydin. Expression of vasodilator-stimulated phosphoprotein in human placenta: possible implications in trophoblast invasion. Mol Hum Reprod. 2002 Jan;8(1):88–94. doi: 10.1093/molehr/8.1.88. [DOI] [PubMed] [Google Scholar]
  18. Liu K., Li L., Nisson P. E., Gruber C., Jessee J., Cohen S. N. Reversible tumorigenesis induced by deficiency of vasodilator-stimulated phosphoprotein. Mol Cell Biol. 1999 May;19(5):3696–3703. doi: 10.1128/mcb.19.5.3696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. López-Encuentra Angel, García-Luján Ricardo, Rivas Juan José, Rodríguez-Rodríguez Jesús, Torres-Lanza Juan, Varela-Simo Gonzalo, Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery Comparison between clinical and pathologic staging in 2,994 cases of lung cancer. Ann Thorac Surg. 2005 Mar;79(3):974–979. doi: 10.1016/j.athoracsur.2004.06.004. [DOI] [PubMed] [Google Scholar]
  20. Machesky L. M. Putting on the brakes: a negative regulatory function for Ena/VASP proteins in cell migration. Cell. 2000 Jun 23;101(7):685–688. doi: 10.1016/s0092-8674(00)80879-x. [DOI] [PubMed] [Google Scholar]
  21. Mountain C. F. Revisions in the International System for Staging Lung Cancer. Chest. 1997 Jun;111(6):1710–1717. doi: 10.1378/chest.111.6.1710. [DOI] [PubMed] [Google Scholar]
  22. Naruke T., Tsuchiya R., Kondo H., Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg. 2001 Jun;71(6):1759–1764. doi: 10.1016/s0003-4975(00)02609-6. [DOI] [PubMed] [Google Scholar]
  23. Niebuhr K., Ebel F., Frank R., Reinhard M., Domann E., Carl U. D., Walter U., Gertler F. B., Wehland J., Chakraborty T. A novel proline-rich motif present in ActA of Listeria monocytogenes and cytoskeletal proteins is the ligand for the EVH1 domain, a protein module present in the Ena/VASP family. EMBO J. 1997 Sep 1;16(17):5433–5444. doi: 10.1093/emboj/16.17.5433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Nomori H., Matsuno Y., Noguchi M., Tsugane S., Shimosato Y., Hirohashi S. Adenocarcinoma of the lung with selective metastasis to the lung: clinical, histologic and DNA-cytofluorometric analyses. Jpn J Cancer Res. 1992 Jan;83(1):93–100. doi: 10.1111/j.1349-7006.1992.tb02357.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Poleri Claudia, Morero José Luis, Nieva Beatriz, Vázquez María Fernanda, Rodríguez Cristina, de Titto Ernesto, Rosenberg Moisés. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. Chest. 2003 Jun;123(6):1858–1867. doi: 10.1378/chest.123.6.1858. [DOI] [PubMed] [Google Scholar]
  26. Quinlan Margaret P. Suppression of epithelial cell transformation and induction of actin dependent differentiation by dominant negative Rac1, but not Ras, Rho or Cdc42. Cancer Biol Ther. 2004 Jan 29;3(1):65–70. doi: 10.4161/cbt.3.1.589. [DOI] [PubMed] [Google Scholar]
  27. Sugarbaker D. J. Lung cancer. 6: The case for limited surgical resection in non-small cell lung cancer. Thorax. 2003 Jul;58(7):639–641. doi: 10.1136/thorax.58.7.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Suzuki K., Nagai K., Yoshida J., Nishimura M., Takahashi K., Nishiwaki Y. The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg. 1999 Jul;118(1):145–153. doi: 10.1016/S0022-5223(99)70153-4. [DOI] [PubMed] [Google Scholar]
  29. Sørensen J. B., Hirsch F. R., Gazdar A., Olsen J. E. Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma. Cancer. 1993 May 15;71(10):2971–2976. doi: 10.1002/1097-0142(19930515)71:10<2971::aid-cncr2820711014>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  30. Valaitis J., Warren S., Gamble D. Increasing incidence of adenocarcinoma of the lung. Cancer. 1981 Mar 1;47(5):1042–1046. doi: 10.1002/1097-0142(19810301)47:5<1042::aid-cncr2820470535>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  31. Watanabe S., Tsugane S., Arimoto H., Shimosato Y., Suemasu K., Arai H., Urano Y. Trend of lung cancers in the National Cancer Center of Japan and comparison with that of Japanese pathological autopsy records. Jpn J Cancer Res. 1987 May;78(5):460–466. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES